Splenectomy during chronic lymphocytic leukemia

The combination of discontinuous high‐dose chlorambucil therapy with splenectomy greatly increased the prognosis of aggressive forms of chronic lymphocytic leukemia (CLL). The median survival for 43 patients was 84 months from diagnosis and 48 months from splenectomy. For 15 stage 0, according to Ra...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1987-05, Vol.59 (9), p.1626-1630
Main Authors: Pegourie, Brigitte, Sotto, Jean‐Jacques, Hollard, Daniel, Michallet, Mauricette, Sotto, Marie‐France
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biological and medical sciences
Chlorambucil - therapeutic use
Combined Modality Therapy
Female
Hematologic and hematopoietic diseases
Humans
Leukemia, Lymphoid - drug therapy
Leukemia, Lymphoid - pathology
Leukemia, Lymphoid - surgery
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Liver - pathology
Lymphatic System - pathology
Lymphocytosis
Male
Medical sciences
Middle Aged
Prognosis
Spleen - pathology
Splenectomy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of discontinuous high‐dose chlorambucil therapy with splenectomy greatly increased the prognosis of aggressive forms of chronic lymphocytic leukemia (CLL). The median survival for 43 patients was 84 months from diagnosis and 48 months from splenectomy. For 15 stage 0, according to Rai classification, obtained after splenectomy, duration ranged from 3 to 105 months. The median survival of a group of patients showing “nodular splenic infiltration” was 104 months and superior to that of a group of patients showing “diffuse splenic infiltration” (72 months). In four of 15 cases studied, the peripheral blood lymphocytic clone disappeared after splenectomy.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19870501)59:9<1626::AID-CNCR2820590917>3.0.CO;2-W